Abstract 329P
Background
Breast cancer (BC) radiotherapy (RT) may induce lung damage ranging from radiological changes only to respiratory failure. The evidence of long-term radiation fibrosis (RF) and its impact on lung function and patients reported dyspnea is scarce. The aim of the present study was to evaluate lung function from before RT to up to 12 years after treatment and identify predictors for long-term RF and reduced lung function.
Methods
BC patients (n=250) referred to postoperative RT (2 Gy x 25) were enrolled in a prospective cohort study from February 2007 to October 2008. All assessments were conducted through clinical controls before RT (baseline), at 3, 6 and 12 months and at long-term follow- up ranging from 7-12 years after RT. Lung function was assessed by the pulmonary function tests (PFT) Vital capacity (VC), Forced Expiratory volume in 1second (FEV1), Forced Vital Capacity (FVC) and diffusion capacity for carbon monoxide (DLCO). RF was diagnosed by High Resolution Computer Tomography scans and graded in accordance with the CTCAE version 3.0 criteria. Patient reported dyspnea was assessed by the EORTC QLQ-C30.
Results
VC, FVC, FEV1 and DLCO declined at 3 months after RT and remained low at long-term follow-up except for DLCO which increased up to 12 years after RT. VC, FEV1, and FVC changes from baseline differed between patients treated with chemotherapy and those not treated with chemotherapy. FEV1 changes from baseline differed between locoregional and local radiated patients. A decline in VC, FEV1, and FVC 3 months after RT predicted a decline in PFT up to 12 years (p=0.020, p=0.004, and p=0.020, respectively). At long-term follow-up age was the only patient and treatment-related factor associated with RF (p=0.021). RF was observed in 144 patients (91%), of which 129 (81%) had fibrosis Grade 1 and 15 (9%) had fibrosis Grade 2. 61 (35%) patients reported dyspnea, mainly grade 1.
Conclusions
Pulmonary function deteriorated in the first year and up to 12 years after BC RT. An early decline in VC, FVC and FEV1 predicted further decline at long-term follow-up. RT. Chemotherapy and locoregional RT predicted a decrease in PFT in the first year and for up to 12 years after RT. Older age was associated with RF at long-term follow-up. Few patients reported severe dyspnea.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Norwegian University of Science and Technology, Faculty of Medicine.
Funding
The Liaison Committee for education, research and innovation in Central Norway.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
272P - Primary prevention of bone fractures in patients (pts) with hormone receptor (HR)+ early breast cancer (EBC) during adjuvant hormonal therapy (HT): The predict & prevent project (P&P)
Presenter: Stefania Gori
Session: Poster session 02
273P - A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2
Presenter: Patrick Neven
Session: Poster session 02
274P - Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study
Presenter: Joyce O'Shaughnessy
Session: Poster session 02
275P - Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
Presenter: Francesco Schettini
Session: Poster session 02
276P - Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)
Presenter: Luca Mastrantoni
Session: Poster session 02
277P - Fat body mass independently predicts incident vertebral fractures in breast cancer patients given adjuvant aromatase inhibitor therapy and denosumab
Presenter: Greta Schivardi
Session: Poster session 02
278P - Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer
Presenter: Daan van Dorst
Session: Poster session 02
279P - Early changes in bone turnover biomarkers during AI therapy are related to loss bone mineral density, data of the B-ABLE cohort
Presenter: Tamara Martos Cardenas
Session: Poster session 02
280P - Adjuvant aromatase inhibitors in patients with PIK3CA mutation early breast cancer
Presenter: Kristin Reinhardt
Session: Poster session 02